Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis

Publisher： Karger

E-ISSN： 1423-0232|77|2|124-133

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.2, 2009-07, pp. : 124-133

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PGR polymorphisms and ovarian cancer risk

By  

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (ELECTRONIC), Vol. 41, Iss. 2, 2015-02 ,pp. : 178-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab on Cholangiocarcinoma of the Liver

By  

Oncology Research and Treatment, Vol. 30, Iss. 3, 2007-02 ,pp. : 129-131

Karger

Access to resources Recommend Favorite

Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis

By  

Pancreatology, Vol. 11, Iss. 6, 2012-01 ,pp. : 595-600

Karger

Access to resources Recommend Favorite

Association between Fibroblast Growth Factor Receptor-4 Gene Polymorphism and Risk of Prostate Cancer: A Meta-Analysis

By  

Urologia Internationalis, Vol. 87, Iss. 2, 2011-05 ,pp. : 159-164

Karger

Access to resources Recommend Favorite

Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists

By  

Oncology Research and Treatment, Vol. 33, Iss. 3, 2010-02 ,pp. : 94-98

Karger

Access to resources Recommend Favorite